drugset / Trial / NCT00114309

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

NCT00114309 ↗

Phase 2 Unknown 66 enrolled TransMolecular
RandomizedParallel-groupOpen-labelTreatment

Summary

This drug is being developed to treat a type of brain cancer, glioma. This study was developed to evaluate the safety, time to disease progression and survival rates after treatment.

Timeline

Start
2004-11
Primary completion
2009-03
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject 131I-TM601 Peptide 0.8 mg Other
Subject 131I-TM601 Peptide 1480 mbq Other